Pharmacologic Management of Temporomandibular Disorders

Oral and Maxillofacial Surgery Clinics of North America

Volumn 20, Issue 2, 2008, Pages 197-210

  Hersh, Elliot V ^a   Balasubramaniam, Ramesh ^a   Pinto, Andres ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CAPSAICIN; CORTICOSTEROID; HYPNOTIC SEDATIVE AGENT; MUSCLE RELAXANT AGENT; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

FACE PAIN; HUMAN; REVIEW; TEMPOROMANDIBULAR JOINT DISORDER;

ADRENAL CORTEX HORMONES; ANTI-ANXIETY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; CAPSAICIN; FACIAL PAIN; HUMANS; HYPNOTICS AND SEDATIVES; NARCOTICS; NEUROMUSCULAR AGENTS; SENSORY SYSTEM AGENTS; TEMPOROMANDIBULAR JOINT DISORDERS;

EID: 40649119893     PISSN: 10423699     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coms.2007.12.005     Document Type: Review

References (118)

1. Denucci D.J., Dionne R.A., and Dubner R. Identifying a neurobiologic basis for drug therapy in TMDs. J Am Dent Assoc 127 5 (1996) 581-593
2. Barden J., Edwards J.E., McQuay H.J., et al. Relative efficacy of oral analgesics after third molar extraction. Br Dent J 197 7 (2004) 407-411
3. Hersh E.V., Moore P.A., and Ross G.L. Over-the counter analgesics and antipyretics: A critical assessment. Clin Ther 22 5 (2000) 500-548
4. Cooper S.A., Needle S.E., and Kruger G.O. Comparative analgesic potency of aspirin and ibuprofen. J Oral Surg 35 11 (1977) 898-903
5. Dionne R.A., and Cooper S.A. Delaying the onset of postoperative dental pain by pretreatment with ibuprofen. Oral Surg Oral Med Oral Pathol 45 6 (1978) 851-856
6. Forbes J.A., Kolodny A.L., Beaver W.T., et al. 12-hour evaluation of the analgesic efficacy of diflunisal, acetaminophen, an acetaminophen-codeine combination, and placebo in postoperative pain. Pharmacotherapy 3 2pt 2 (1983) 47S-54S
7. Hersh E.V., Levin L.M., Cooper S.A., et al. Ibuprofen liquigel in oral surgery pain. Clin Ther 22 11 (2000) 1306-1318
8. Chang D.J., Fricke J.R., Bird S.R., et al. Rofecoxib versus codeine/acetaminophen in postoperative dental pain: a double-blind, randomized, placebo- and active comparator-controlled clinical trial. Clin Ther 23 9 (2001) 1446-1455
9. Cooper S.A., Precheur H., Rauch D., et al. Evaluation of oxycodone and acetaminophen in treatment of postoperative dental pain. Oral Surg Oral Med Oral Pathol 50 6 (1980) 496-501
10. Van Dyke T., Litkowski L.J., Kiersch T.A., et al. Combination oxycodone 5 mg/ibuprofen 400 mg for the treatment of postoperative pain: a double-blind, placebo- and active-controlled parallel-group study. Clin Ther 26 12 (2004) 2003-2014
11. Hersh E.V. Mechanisms of pain. In: Pertes R.A., and Gross S.G. (Eds). Clinical management of temporomandibular disorders and orofacial pain (1995), Quintessence Publishing Co, Inc., Carol Stream (IL) 35-44
12. Dionne R.A. Pharmacologic approaches. In: Laskin D.M., Greene C.S., and Hylander W.L. (Eds). TMDs: an evidence-based approach to diagnosis and treatment (2006), Quintessence Publishing Co, Inc., Hanover Park (IL) 347-357
13. Paul R.E., and Hersh E.V. Clinical pharmacology of chronic orofacial pain medications. Compend Contin Educ Dent 10 9 (1989) 492-498
14. Hersh E.V., Lally E.T., and Moore P.A. Update of cyclooxygenase inhibitors: Has a third COX isoform entered the fray?. Curr Med Res Opin 21 (2005) 1217-1226
15. Bombadier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 1520-1528
16. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study-a randomized controlled trial. JAMA 284 (2000) 1247-1255
17. Schitnizer T.J., Burmester G.R., Mysler E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial. Lancet 364 (2004) 665-674
18. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
19. Solomon S.D., McMurray J.J.V., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
20. Nussmeier N.A., Whelton A.A., Brown M.T., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 1081-1091
21. Ta L.E., and Dionne R.A. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen. Pain 111 (2004) 13-21
22. Singer E.J., and Dionne R.A. A controlled evaluation of diazepam and ibuprofen for chronic orofacial pain. J Orofac Pain 11 (1997) 139-147
23. Gordon S.M., Montgomery M.T., and Jones D. Comparative efficacy of piroxicam versus placebo for temporomandibular pain. J Dent Res 69 special issue (1990) 218
24. Di Rienzo Businco L., Di Rienzo Businco A., D'Emilia M., et al. Topical versus systemic diclofenac in the treatment of temporo-mandibular joint dysfunction symptoms. Acta Otorhinolaryngol Ital 24 5 (2004) 279-283
25. Brater C.D., Harris C., Redfern J.S., et al. Renal effects of COX-2-selective inhibitors. Am J Nephrol 21 (2001) 1-15
26. Curtis S.P., Ng J., Yu Q., et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 26 (2004) 70-83
27. Dalton S.O., Johansen C., Mellemkjaer L., et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 163 (2003) 59-64
28. De Abajo F.J., Rodriguez L.A., and Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. Br Med J 319 (1999) 1106-1109
29. Schiffman E.L., Look J.O., Hodges J.S., et al. Randomized effectiveness study of four therapeutic strategies for TMJ closed lock. J Dent Res 86 1 (2007) 58-63
30. Arabshahi B., Dewitt E.M., Cahill A.M., et al. Utility of corticosteroid injection for temporomandibular arthritis in children with juvenile idiopathic arthritis. Arthritis Rheum 52 11 (2005) 3563-3569
31. Fredriksson L., Alstergren P., and Kopp S. Serotonergic mechanisms influence the response to glucocorticoid treatment in TMJ arthritis. Mediators Inflamm 4 (2005) 194-201
32. Schindler C., Paessler L., Eckelt U., et al. Severe temporomandibular dysfunction and joint destruction after intra-articular injection of triamcinolone. J Oral Pathol Med 34 (2003) 184-186
33. Schieffer B.M., Pham Q., Labus J., et al. Pain medication beliefs and medication misuse in chronic pain. J Pain 6 9 (2005) 620-629
34. Trescot A.M., Boswell M.V., Atluri S.L., et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 9 1 (2006) 1-39
35. Portenoy R.K., Messina J., Xie F., et al. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin 23 1 (2007) 223-233
36. Dionne R.A. Pharmacologic treatments for temporomandibular disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 83 1 (1997) 134-142
37. Swift J.Q., and Roszkowski M.T. The use of opioid drugs in management of chronic orofacial pain. J Oral Maxillofac Surg 56 9 (1998) 1081-1085
38. Brennan P.A., and Hankorvan V. Arthrocentesis for temporomandibular joint pain dysfunction syndrome. J Oral Maxillofac Surg 64 6 (2006) 949-951
39. Furst I.M., Kryshtalskyj B., and Weinberg S. The use of intra-articular opioids and bupivacaine for analgesia following temporomandibular joint arthroscopy: a prospective randomized trial. J Oral Maxillofac Surg 59 9 (2001) 979-983
40. List T., Tegelberg A., Haroldson T., et al. Intra-articular morphine as analgesic in temporomandibular joint arthralgia/osteoarthritis. Pain 94 3 (2001) 275-282
41. Hayashi K., Sugisaiki M., Ota S., et al. mu-Opioid receptor mRNA expression and immunohistochemical localization in the rat temporomandibular joint. Peptides 23 5 (2002) 889-893
42. Mehlisch D.R. Double-blind, single-dose comparison of bromfenac sodium, tramadol, and placebo after oral surgery. J Clin Pharmacol 38 5 (1998) 455-462
43. Fricke Jr. J.R., Hewitt D.J., Jordan D.M., et al. A double-blind placebo-controlled comparison of tramadol/acetaminophen and tramadol in patients with postoperative dental pain. Pain 109 3 (2004) 250-257
44. Fricke Jr. J.R., Karim R., Jordan D., et al. A double-blind, single-dose comparison of the analgesic efficacy of tramadol/acetaminophen combination tablets, hydrocodone/acetaminophen combination tablets, and placebo after oral surgery. Clin Ther 24 6 (2002) 953-968
45. Cepeda M.S., Camargo F., Zea C., et al. Tramadol for osteoarthritis: a systematic review and meta analysis. J Rheumatol 34 3 (2007) 543-555
46. Malonne H., Coffiner M., Sonet B., et al. Efficacy and tolerability of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 26 11 (2004) 1774-1782
47. Schnitzer T.J., Gray W.L., Paster R.Z., et al. Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol 27 3 (2000) 772-778
48. Ruoff G.E., Rosenthal N., Jordan D., et al. Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebo-controlled outpatient study. Clin Ther 25 4 (2003) 1123-1141
49. Bennett R.M., Schein J., Kosinski M.R., et al. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum 53 4 (2005) 519-527
50. Freeman R., Raskin P., Hewitt D.J., et al. Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin 23 1 (2007) 147-161
51. Perrot S., Krause D., Crozes P., et al. Efficacy and tolerability of paracetamol/tramadol (325 mg/37.5 mg) combination treatment compared with tramadol (50 mg) monotherapy in patients with subacute low back pain: a multicenter, randomized, double-blind, parallel-group, 10-day treatment study. Clin Ther 28 10 (2006) 1592-1606
52. Enggaard T.P., Poulsen L., Arendt-Nielsen L., et al. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg 102 1 (2006) 146-150
53. Lee C.R., McTavish D., and Sorkin E.M. Tramadol: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 46 2 (1993) 313-340
54. Raffa R.B., Friderichs E., Reimann W., et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an "atypical" opioid analgesic. J Pharmacol Exp Ther 260 1 (1992) 275-285
55. Hersh E.V., and Moore P.A. Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc 135 3 (2004) 298-311
56. Laugesen S., Enggaard T.P., Pedersen R.S., et al. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 77 4 (2005) 312-323
57. Shatin D., Gardner J.S., Stergachis A., et al. Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants. Pharmacoepidemiol Drug Saf 14 3 (2005) 149-154
58. Gillman P.K. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 95 4 (2005) 434-441
59. Taylor D.J., Mallory L.J., Lichstein K.L., et al. Comorbidity of chronic insomnia with medical problems. Sleep 30 2 (2007) 213-218
60. Moore P.A. Sedative-hypnotics, antianxiety drugs, and centrally acting muscle relaxants. In: Yagiela J.A., Dowd F.J., and Neidle E.A. (Eds). Pharmacology and therapeutics for dentistry. 5th edition (2004), Elsevier Mosby, St Louis 193-218
61. Harkins S., Linford J., Cohen J., et al. Administration of clonazepam in the treatment of TMD and associated myofascial pain: a double-blind pilot study. Craniomandib Disord 5 3 (1991) 179-186
62. DeNucci D.J., Sobiski C., and Dionne R.A. Triazolam improves sleep but fails to alter pain in TMD patients. J Orofac Pain 12 2 (1998) 116-123
63. Laroche M.L., Charmes J.P., Nouaille Y., et al. Is inappropriate medication use a major cause of adverse drug reactions in the elderly?. Br J Clin Pharmacol 63 2 (2007) 177-186
64. Yatani H., Studts J., Cordova M., et al. Comparison of sleep quality and clinical and psychologic characteristics in patients with temporomandibular disorders. J Orofac Pain 16 3 (2002) 221-228
65. Sanger D.J. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 18 Suppl 1 (2004) 9-15
66. Harazin J., and Berigan T.R. Zolpidem tartrate and somnambulism. Mil Med 164 9 (1999) 669-670
67. Sharma A., and Dewan V.K. A case report of zolpidem-induced somnambulism. Prim Care Companion J Clin Psychiatry 7 2 (2005) 74
68. Yang W., Dollear M., and Muthukrishnan S.R. One rare side effect of zolpidem-sleepwalking: a case report. Arch Phys Med Rehabil 86 6 (2005) 1265-1266
69. Borja N.L., and Daniel K.L. Ramelteon for the treatment of insomnia. Clin Ther 28 10 (2006) 1540-1555
70. Toth P.P., and Urtis J. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther 26 9 (2004) 1355-1367
71. Rizzatti-Barbosa C.M., Martinelli D.A., Ambrosano G.M., et al. Therapeutic response of benzodiazepine, orphenadrine citrate and occlusal splint association in TMD pain. Cranio 21 2 (2003) 116-120
72. Brown Jr. B.R., and Womble J. Cyclobenzaprine in intractable pain syndromes with muscle spasm. JAMA 240 11 (1978) 1151-1152
73. Borenstein D.G., and Korn S. Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials. Clin Ther 25 4 (2003) 1056-1073
74. Herman C.R., Schiffman E.L., Look J.O., et al. The effectiveness of adding pharmacologic treatment with clonazepam or cyclobenzaprine to patient education and self-care for the treatment of jaw pain upon awakening: a randomized clinical trial. J Orofac Pain 16 1 (2002) 64-70
75. Deal C.L., Schnitzer T.J., Lipstein E., et al. Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther 13 3 (1991) 383-395
76. Altman R.D., Aven A., Holmburg C.E., et al. Capsaicin cream 0.25% as monotherapy for osteoarthritis: a double-blind study. Semin Arthritis Rheum 23 (1994) 25-33
77. McCleane G. The analgesic efficacy of topical capsaicin is enhanced by glycerol trinitrate in painful osteoarthritis: a randomized, double blind, placebo controlled trial. Eur J Pain 4 (2000) 355-360
78. Watson C.P., Tyler K.L., Bickers D.R., et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther 15 (1993) 510-526
79. Homulund A., Ekblom A., Hansson P., et al. Concentrations of neuropeptides substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y, and vasoactive intestinal polypeptide in synovial fluid of the human temporomandibular joint. Int J Oral Maxillofac Surg 20 (1991) 228-231
80. Kopp S. The influence of neuropeptides, serotonin, and interleukin 1ß on temporomandibular joint pain and inflammation. J Oral Maxillofac Surg 56 (1998) 189-191
81. Sato J., Segami N., Yoshitake Y., et al. Expression of capsaicin receptor TRPV-1 in synovial tissues of patients with symptomatic internal derangement of the temporomandibular joint and joint pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100 (2005) 674-681
82. Hersh E.V., Pertes R.A., and Ochs H. Topical capsaicin: pharmacology and therapeutic potential in the treatment of temporomandibular pain. J Clin Dent 5 (1994) 54-59
83. Padilla M., Clark G.T., and Merrill R.L. Topical medications for orofacial neuropathic pain: a review. J Am Dent Assoc 131 2 (2000) 184-195
84. Comer A.M., and Lamb H.M. Lidocaine patch 5%. Drugs 59 2 (2000) 245-249
85. Campbell B.J., Rowbotham M., Davies P.S., et al. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci 91 5 (2002) 1343-1350
86. Rowbotham M.C., Davies P.S., Verkempinck C., et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 65 1 (1996) 39-44
87. Galer B.S., Rowbotham M.C., Perander J., et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 80 3 (1999) 533-538
88. Galer B.S., Jensen M.P., Ma T., et al. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain 18 5 (2002) 297-301
89. Galer B.S., Gammaitoni A.R., Oleka N., et al. Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain. Curr Med Res Opin 20 Suppl 2 (2004) S5-S12
90. Galer B.S., Sheldon E., Patel N., et al. Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis. Curr Med Res Opin 20 9 (2004) 1455-1458
91. The top 300 prescriptions for 2005 by number of US prescriptions dispensed. Available at: http://www.rxlist.com/top300.htm. Accessed April 04, 2007.
92. Mico J.A., Ardid D., Berrocoso E., et al. Antidepressants and pain. Trends Pharmacol Sci 27 7 (2006) 348-354
93. Alcoff J., Jones E., Rust P., et al. Controlled trial of imipramine for chronic low back pain. J Fam Pract 14 5 (1982) 841-846
94. Jenkins D.G., Ebbutt A.F., and Evans C.D. Tofranil in the treatment of low back pain. J Int Med Res 4 Suppl 2 (1976) 28-40
95. Watson C.P., Evans R.J., Reed K., et al. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 32 6 (1982) 671-673
96. Monks R., and Merskey H. Psychotropic drugs. In: Bonica J.J., Wall P.D., and Melzack R. (Eds). The textbook of pain (1984), Churchill Livingstone Co, Edinburgh, UK 526-537
97. Goldstein D.J., Lu Y., Detke M.J., et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116 1-2 (2005) 109-118
98. Arnold L.M., Rosen A., Pritchett Y.L., et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119 1-3 (2005) 5-15
99. Hersh E.V. Tricyclic antidepressant drugs: pharmacologic implications in the treatment of chronic orofacial pain. Compend Contin Educ Dent 8 9 (1987) 688-693
100. Rizzatti-Barbosa C.M., Nogueira M.T., de Andrade E.D., et al. Clinical evaluation of amitriptyline for the control of chronic pain caused by temporomandibular joint disorders. Cranio 21 3 (2003) 221-225
101. Plesh O., Curtis D., Levine J., et al. Amitriptyline treatment of chronic pain in patients with temporomandibular disorders. J Oral Rehabil 27 10 (2000) 834-841
102. Sporer K.A. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf 13 2 (1995) 94-104
103. Spira P.J., and Beran R.G. Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology 61 12 (2003) 1753-1759
104. Arnold L.M., Goldenberg D.L., Stanford S.B., et al. Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 56 4 (2007) 1336-1344
105. Berry J.D., and Petersen K.L. A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. Neurology 65 3 (2005) 444-447
106. Pandey C.K., Raza M., Tripathi M., et al. The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barre syndrome patients in the intensive care unit. Anesth Analg 101 1 (2005) 220-225
107. Gorson K.C., Schott C., Herman R., et al. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 66 2 (1999) 251-252
108. Rowbotham M., Harden N., Stacey B., et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280 21 (1998) 1837-1842
109. Backonja M., Beydoun A., Edwards K.R., et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280 21 (1998) 1831-1836
110. Backonja M.M. Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. Epilepsia 40 Suppl 6 (1999) S57-S59
111. Serpell M.G. Neuropathic pain study group. Gabapentin in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Pain 99 3 (2002) 557-566
112. Tassone D.M., Boyce E., Guyer J., et al. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 29 1 (2007) 26-48
113. van Seventer R., Feister H.A., Young Jr. J.P., et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 22 2 (2006) 375-384
114. Freynhagen R., Strojek K., Griesing T., et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 115 3 (2005) 254-263
115. Richter R.W., Portenoy R., Sharma U., et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 6 4 (2005) 253-260
116. Lesser H., Sharma U., LaMoreaux L., et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 63 11 (2004) 2104-2110
117. Sabatowski R., Galvez R., Cherry D.A., et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 109 1-2 (2004) 26-35
118. Kimos P., Biggs C., Mah J., et al. Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial. Pain 127 1-2 (2007) 151-160